UNSPSC 51101650: Dehydroemetine

This classification denotes an antiprotozoal agent with the molecular formula C29H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7S79QT1T91, chemically known as 2,3-didehydroemetine dihydrochloride (.+-.)- but generally known as dehydroemetine, which bears US NIH Compound Identifier 17558. European Medicines Agency schedules Dehydroemetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06946MIG. The term DEHYDROEMETINE is an International Non-Proprietary Name.

UNSPSC 51101650 Dehydroemetine is a Commodity code that nominally names a specific pharmaceutical alkaloid, but recent state and local solicitations tagged to this code do not reflect procurement of dehydroemetine itself. Instead, issuing bodies are using the code to solicit broad-spectrum pharmaceutical products and public-health supplies, including antibiotics, opioid-reversal agents, and drug deactivation systems. The Illinois Department of Public Health and Seminole County, Florida have posted opportunities in this classification, signaling that state and local purchasing offices may be conflating specific drug codes or using a catch-all pharmaceutical taxonomy entry for multi-product health procurement.

The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 under Bid Number 26-482DPH-PREPD-B-53392 for doxycycline hyclate and ciprofloxacin hydrochloride tablets, totaling $2,999,999.11 over a 12-month initial term with two renewal options, selected as the lowest responsive and responsible bidder through an IFB process. Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, originally due July 26, 2026. Recent activity is concentrated in Florida and Illinois; the mismatch between the code's nominal scope and the actual products being solicited suggests either miscoding by purchasing offices or an overly broad catch-all classification in the state and local taxonomy—vendors should verify the specific pharmaceutical products required in any RFP or IFB before submitting a bid.